Overview

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Treatments:

Enoxaparin
Factor Xa Inhibitors
Rivaroxaban